Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS

(MedPage Today) -- The investigational anti-CD47 monoclonal antibody magrolimab combined with azacitidine showed promising efficacy and was well tolerated in patients with untreated higher-risk myelodysplastic syndromes (MDS), according to a phase...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news